# OnCo record colorectal-cancer-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/colorectal-cancer-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "colorectal-cancer-signalling" ;
  schema:name "Colorectal cancer (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05210"@en, "Colorectal cancer"@en ;
  schema:description "This KEGG map traces the step-by-step genetic route from normal bowel lining to colorectal cancer: APC loss unleashes Wnt, KRAS mutation drives growth, then TP53 and TGF-beta/SMAD4 loss remove the last brakes, or alternatively mismatch repair fails and mutations pile up. Knowing which route a tumour took decides which drugs work."@en ;
  schema:url <https://onco.cc/pathways/colorectal-cancer-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05210>, <https://doi.org/10.1016/S0140-6736(19)32319-0> ;
  onco:related <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/pathways/tgf-beta/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/trifluridine-tipiracil/> ;
  onco:pathways <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/tgf-beta/>, <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/pathways/apoptosis-bcl2/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/vegf-angiogenesis/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-dekker-lancet/> .